a Centers for Disease Control and Prevention.
For US Residents Only
Sanofi Pasteur Menactra
Meningococcal
(Groups A, C, Y and W-135)
Polysaccharide Diphtheria
Toxoid Conjugate Vaccine
Meningococcal
(Groups A, C, Y and W-135)
Polysaccharide Diphtheria
Toxoid Conjugate Vaccine
- E-mail a Friend
- A A Text Resize
- Prescribing Information
- Safety Information
Important Safety Information
Indication
Menactra vaccine is given to people 9 months through 55 years of age to help prevent meningococcal disease (including meningitis) caused by certain strains of meningococcal bacteria. Menactra vaccine is not indicated for the prevention of meningitis caused by meningococcal strains not contained in the vaccine.
Safety Information
Side effects to Menactra vaccine include injection site pain, redness, swelling, headache and tiredness. In infants, irritability, crying, drowsiness, loss of appetite, and diarrhea. Other side effects may occur.
Vaccination should be avoided by persons with known hypersensitivity (severe allergic reaction) to any ingredient of the vaccine. Persons previously diagnosed with Guillain-Barré syndrome (GBS - severe muscle weakness) may have an increased chance of getting GBS following vaccination. Vaccination with Menactra vaccine may not protect all individuals.
For more information about Menactra vaccine, talk to your health-care professional.